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Table 1. Incidence of new-onset non-hematologic adverse events regardless of causality.
Patients (%) 0 to less than 6 to less than 12 to less than 18 to less than 24 months 
6 months 12 months 18 months 24 months or more
Ruxolitinib Placebo Ruxolitinib Ruxolitinib Ruxolitinib Ruxolitinib
Fatigue 25.7 31.9 5.8 7.9 8.4 5.4
Diarrhea 23.2 22.9 5.7 5.7 3.4 10.3
Ecchymosis 18.1 9.2 5.5 4.3 1.6 0
Dyspnea 16.8 16.1 4.5 6.4 4.8 4.9
Peripheral edema 16.7 23.2 5.3 6.3 4.8 5.1
Headache 15.5 5.0 0.9 2.1 1.5 0
Dizziness 14.2 6.5 5.3 6.5 3.2 4.5
Nausea 12.8 17.0 5.2 3.0 0 8.0
Constipation 12.0 12.1 4.2 5.9 4.3 8.7
Vomiting 12.0 10.8 2.5 1.0 0 4.0
Pain in extremity 11.4 10.7 8.5 4.3 1.6 0
Pyrexia 11.3 6.4 2.4 3.7 6.7 8.2
Insomnia 10.7 10.7 4.2 2.0 2.8 4.1
Abdominal pain 10.1 40.7 5.0 4.9 0 8.2
Arthralgia 10.1 7.9 2.5 5.0 0 4.4
For each time interval, the effective sample size of the interval was used as the denominator. The effective sample size=the number of patients at risk at the beginning of the interval
plus half of the censored patients during the time interval. Because all patients receiving placebo had either crossed over to ruxolitinib treatment or discontinued from the study
after the primary analysis and therefore only a subset of these patients had data beyond 6 months, the incidence of adverse events after 6 months was summarized only for patients
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